Brokerages expect Revance Therapeutics, Inc. (NASDAQ:RVNC) to post earnings per share (EPS) of ($0.94) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Revance Therapeutics’ earnings. The lowest EPS estimate is ($1.01) and the highest is ($0.87). Revance Therapeutics reported earnings per share of ($0.64) during the same quarter last year, which indicates a negative year over year growth rate of 46.9%. The firm is scheduled to announce its next earnings results on Thursday, November 2nd.
On average, analysts expect that Revance Therapeutics will report full-year earnings of ($3.57) per share for the current fiscal year, with EPS estimates ranging from ($3.86) to ($3.00). For the next fiscal year, analysts anticipate that the firm will post earnings of ($3.38) per share, with EPS estimates ranging from ($4.05) to ($2.85). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.03. Revance Therapeutics had a negative return on equity of 55.21% and a negative net margin of 32,936.67%. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same period last year, the business earned ($0.88) EPS. The business’s revenue was up .0% on a year-over-year basis.
Several equities research analysts have commented on RVNC shares. Zacks Investment Research raised Revance Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a report on Tuesday, August 22nd. Piper Jaffray Companies set a $28.00 target price on Revance Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 26th. BidaskClub raised Revance Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 target price on shares of Revance Therapeutics in a report on Wednesday, September 6th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $35.20.
Shares of Revance Therapeutics (NASDAQ:RVNC) traded up 1.34% during trading on Wednesday, reaching $26.45. The company’s stock had a trading volume of 64,597 shares. The stock’s 50 day moving average is $25.69 and its 200 day moving average is $23.53. Revance Therapeutics has a one year low of $12.35 and a one year high of $28.75. The firm’s market cap is $815.16 million.
In other news, CEO L Daniel Browne sold 22,800 shares of the company’s stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $22.76, for a total transaction of $518,928.00. Following the transaction, the chief executive officer now directly owns 178,850 shares of the company’s stock, valued at $4,070,626. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Lauren P. Silvernail sold 11,164 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $26.67, for a total value of $297,743.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,564 shares of company stock worth $995,880. Corporate insiders own 18.86% of the company’s stock.
Large investors have recently made changes to their positions in the company. Swiss National Bank lifted its holdings in Revance Therapeutics by 6.8% in the first quarter. Swiss National Bank now owns 32,850 shares of the biopharmaceutical company’s stock valued at $683,000 after acquiring an additional 2,100 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in Revance Therapeutics by 5.9% in the first quarter. Parametric Portfolio Associates LLC now owns 27,401 shares of the biopharmaceutical company’s stock valued at $570,000 after acquiring an additional 1,524 shares during the period. Victory Capital Management Inc. bought a new position in Revance Therapeutics in the first quarter valued at about $739,000. American International Group Inc. lifted its holdings in Revance Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 834 shares during the period. Finally, FMR LLC lifted its holdings in Revance Therapeutics by 216.9% in the first quarter. FMR LLC now owns 316,900 shares of the biopharmaceutical company’s stock valued at $6,592,000 after acquiring an additional 216,900 shares during the period. 89.32% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/10/27/0-94-earnings-per-share-expected-for-revance-therapeutics-inc-rvnc-this-quarter.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.